Trans-Trimethoxyresveratrol

Trans-Trimethoxyresveratrol (trans-trismethoxy Resveratrol; (E) -Resveratrol trimethyl ether; trans-3,5,4'-Trimethoxystilbene) is an orally active natural derivative of Resveratrol (HY-16561) . Trans-Trimethoxyresveratrol has an enhanced anticancer profile compared to Resveratrol, exhibiting higher potency than resveratrol, with improved cancer cell proliferation inhibition, induction of cell cycle arrest, decreased metastasis, and increased apoptosis. Trans-Trimethoxyresveratrol causes microtubule disassembling and tubulin depolymerization and exerts anti-angiogenic effects through VEGFR2. Trans-Trimethoxyresveratrol can be used for the studies of anti-angiogenic and anti-cancer (such as non-small cell lung cancer and osteosarcoma) [1][2][3][4][5][6].

Product Specifications

CAS Number

[22255-22-7]

Product Name Alternative

Trans-trismethoxy Resveratrol; (E) -Resveratrol trimethyl ether; trans-3,5,4'-Trimethoxystilbene

UNSPSC

12352005

Hazard Statement

H315, H318, H335, H410

Target

Apoptosis; Caspase; Reactive Oxygen Species (ROS) ; VEGFR

Type

Natural Products

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/trans-Trimethoxyresveratrol.html

Purity

99.35

Solubility

DMSO : ≥ 50 mg/mL|H2O : < 0.1 mg/mL (ultrasonic)

Smiles

COC1=CC=C(/C=C/C2=CC(OC)=CC(OC)=C2)C=C1

Molecular Formula

C17H18O3

Molecular Weight

270.32

Precautions

H315, H318, H335, H410

References & Citations

[1]Aldawsari FS, Velázquez-Martínez CA. 3,4',5-trans-Trimethoxystilbene; a natural analogue of resveratrol with enhanced anticancer potency. Invest New Drugs. 2015 Jun;33 (3) :775-86. |[2]Belleri M, et al. Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4'-trimethoxystilbene. Mol Pharmacol. 2005 May;67 (5) :1451-9. |[3]Alex D, et al. Resveratrol derivative, trans-3,5,4'-trimethoxystilbene, exerts antiangiogenic and vascular-disrupting effects in zebrafish through the downregulation of VEGFR2 and cell-cycle modulation. J Cell Biochem. 2010 Feb 1;109 (2) :339-46. |[4]Lu M, et al. Trans-3,5,4´-trimethoxystilbene reduced gefitinib resistance in NSCLCs via suppressing MAPK/Akt/Bcl-2 pathway by upregulation of miR-345 and miR-498. J Cell Mol Med. 2019 Apr;23 (4) :2431-2441. |[5]Lin HS, Ho PC. Preclinical pharmacokinetic evaluation of resveratrol trimethyl ether in sprague-dawley rats: the impacts of aqueous solubility, dose escalation, food and repeated dosing on oral bioavailability. J Pharm Sci. 2011 Oct;100 (10) :4491-500. |[6]Feng Y, et al. Resveratrol Derivative, Trans-3, 5, 4'-Trimethoxystilbene Sensitizes Osteosarcoma Cells to Apoptosis via ROS-Induced Caspases Activation. Oxid Med Cell Longev. 2021 Mar 25;2021:8840692.